FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195718493> ?p ?o ?g. }

• W3195718493 abstract "Treatment options for poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine refractory thyroid carcinoma, but response to single agent is poor in ATC. Recent reports of combining LEN with PD-1 inhibitor pembrolizumab (PEM) are promising.Primary ATC (n=93) and PDTC (n=47) tissue samples diagnosed 1997-2019 at five German tertiary care centers were assessed for PD-L1 expression by immunohistochemistry using Tumor Proportion Score (TPS). FGFR 1-4 mRNA was quantified in 31 ATC and 14 PDTC with RNAscope in-situ hybridization. Normal thyroid tissue (NT) and papillary thyroid carcinoma (PTC) served as controls. Disease specific survival (DSS) was the primary outcome variable.PD-L1 TPS≥50% was observed in 42% of ATC and 26% of PDTC specimens. Mean PD-L1 expression was significantly higher in ATC (TPS 30%) than in PDTC (5%; p<0.01) and NT (0%, p<0.001). 53% of PDTC samples had PD-L1 expression ≤5%. FGFR mRNA expression was generally low in all samples but combined FGFR1-4 expression was significantly higher in PDTC and ATC compared to NT (each p<0.001). No impact of PD-L1 and FGFR 1-4 expression was observed on DSS.High tumoral expression of PD-L1 in a large proportion of ATCs and a subgroup of PDTCs provides a rationale for immune checkpoint inhibition. FGFR expression is low thyroid tumor cells. The clinically observed synergism of PEM with LEN may be caused by immune modulation." @default.
• W3195718493 created "2021-08-30" @default.
• W3195718493 creator A5000676414 @default.
• W3195718493 creator A5007171110 @default.
• W3195718493 creator A5009744971 @default.
• W3195718493 creator A5011930045 @default.
• W3195718493 creator A5023421590 @default.
• W3195718493 creator A5024897705 @default.
• W3195718493 creator A5030747264 @default.
• W3195718493 creator A5031832059 @default.
• W3195718493 creator A5039374580 @default.
• W3195718493 creator A5042079657 @default.
• W3195718493 creator A5042684212 @default.
• W3195718493 creator A5051921739 @default.
• W3195718493 creator A5062913601 @default.
• W3195718493 creator A5070640664 @default.
• W3195718493 creator A5071064116 @default.
• W3195718493 creator A5074235926 @default.
• W3195718493 creator A5076424284 @default.
• W3195718493 creator A5091230949 @default.
• W3195718493 date "2021-08-12" @default.
• W3195718493 modified "2023-10-17" @default.
• W3195718493 title "FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale" @default.
• W3195718493 cites W1965175058 @default.
• W3195718493 cites W1967792499 @default.
• W3195718493 cites W1982488143 @default.
• W3195718493 cites W1991662589 @default.
• W3195718493 cites W2020679577 @default.
• W3195718493 cites W2106787323 @default.
• W3195718493 cites W2113134419 @default.
• W3195718493 cites W2129781341 @default.
• W3195718493 cites W2332521027 @default.
• W3195718493 cites W2535032472 @default.
• W3195718493 cites W2550457171 @default.
• W3195718493 cites W2560367415 @default.
• W3195718493 cites W2566739302 @default.
• W3195718493 cites W2572174216 @default.
• W3195718493 cites W2604320765 @default.
• W3195718493 cites W2766581537 @default.
• W3195718493 cites W2803019317 @default.
• W3195718493 cites W2832528908 @default.
• W3195718493 cites W2894361335 @default.
• W3195718493 cites W2902083233 @default.
• W3195718493 cites W2951548994 @default.
• W3195718493 cites W2961928477 @default.
• W3195718493 cites W2978592754 @default.
• W3195718493 cites W2979813691 @default.
• W3195718493 cites W2979970262 @default.
• W3195718493 cites W2984119413 @default.
• W3195718493 cites W2990363299 @default.
• W3195718493 cites W2990602950 @default.
• W3195718493 cites W2995417642 @default.
• W3195718493 cites W3004519161 @default.
• W3195718493 cites W3008329485 @default.
• W3195718493 cites W3011426038 @default.
• W3195718493 cites W3021719484 @default.
• W3195718493 cites W3032358754 @default.
• W3195718493 cites W3042946930 @default.
• W3195718493 cites W3047570563 @default.
• W3195718493 cites W3124581135 @default.
• W3195718493 cites W3137149901 @default.
• W3195718493 cites W3163554595 @default.
• W3195718493 doi "https://doi.org/10.3389/fendo.2021.712107" @default.
• W3195718493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8406771" @default.
• W3195718493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34475850" @default.
• W3195718493 hasPublicationYear "2021" @default.
• W3195718493 type Work @default.
• W3195718493 sameAs 3195718493 @default.
• W3195718493 citedByCount "15" @default.
• W3195718493 countsByYear W31957184932021 @default.
• W3195718493 countsByYear W31957184932022 @default.
• W3195718493 countsByYear W31957184932023 @default.
• W3195718493 crossrefType "journal-article" @default.
• W3195718493 hasAuthorship W3195718493A5000676414 @default.
• W3195718493 hasAuthorship W3195718493A5007171110 @default.
• W3195718493 hasAuthorship W3195718493A5009744971 @default.
• W3195718493 hasAuthorship W3195718493A5011930045 @default.
• W3195718493 hasAuthorship W3195718493A5023421590 @default.
• W3195718493 hasAuthorship W3195718493A5024897705 @default.
• W3195718493 hasAuthorship W3195718493A5030747264 @default.
• W3195718493 hasAuthorship W3195718493A5031832059 @default.
• W3195718493 hasAuthorship W3195718493A5039374580 @default.
• W3195718493 hasAuthorship W3195718493A5042079657 @default.
• W3195718493 hasAuthorship W3195718493A5042684212 @default.
• W3195718493 hasAuthorship W3195718493A5051921739 @default.
• W3195718493 hasAuthorship W3195718493A5062913601 @default.
• W3195718493 hasAuthorship W3195718493A5070640664 @default.
• W3195718493 hasAuthorship W3195718493A5071064116 @default.
• W3195718493 hasAuthorship W3195718493A5074235926 @default.
• W3195718493 hasAuthorship W3195718493A5076424284 @default.
• W3195718493 hasAuthorship W3195718493A5091230949 @default.
• W3195718493 hasBestOaLocation W31957184931 @default.
• W3195718493 hasConcept C121608353 @default.
• W3195718493 hasConcept C126322002 @default.
• W3195718493 hasConcept C142724271 @default.
• W3195718493 hasConcept C143998085 @default.
• W3195718493 hasConcept C170493617 @default.
• W3195718493 hasConcept C204232928 @default.
• W3195718493 hasConcept C2776264508 @default.
• W3195718493 hasConcept C2777701055 @default.

• next